TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional) | RFA DE 25 003

Opportunity Information: Apply for RFA DE 25 003

The TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) funding opportunity (RFA-DE-25-003) is a National Institutes of Health (NIH) cooperative agreement (U54) designed to build and operate a national, interdisciplinary research consortium focused on Temporomandibular Disorders (TMDs). The core purpose is to speed progress across the full pipeline of TMD research, from basic science discoveries to clinical research and, ultimately, translation into evidence-based treatments and better clinical care. A key emphasis is patient-centered translational research, meaning the consortium is expected to align research priorities, study designs, and outcomes with the needs and lived experiences of people affected by TMDs, while also producing results that can realistically be implemented in real-world healthcare settings.

Because this is a U54 cooperative agreement, applicants should expect substantial NIH involvement beyond standard grant oversight. In practice, that typically means NIH program staff are active partners in shaping consortium activities, coordinating multi-site efforts, and ensuring that shared goals, milestones, and deliverables are met across participating components. The notice also states "Clinical Trial Optional," indicating that applicants may propose clinical trials if they fit the program goals, but a clinical trial is not required for every proposed project. The overall structure is intended to support coordinated, team-based science rather than isolated projects, with an emphasis on collaboration, harmonization of methods, and producing outputs that move the field forward in a unified way.

The consortium is expected to advance several interconnected areas: basic and clinical TMD research, research training, and translation to improved care. This suggests an integrated program that not only generates new knowledge (for example, mechanisms of pain, tissue biology, neural pathways, biopsychosocial contributors, or risk stratification) but also strengthens the workforce and infrastructure needed to sustain TMD research nationally. The translational focus implies attention to developing and validating interventions, improving diagnostics or phenotyping approaches, identifying clinically meaningful outcomes, and closing the gap between research findings and routine clinical practice. The patient-centered angle also signals the importance of outcomes that matter to patients (such as pain interference, function, quality of life, and treatment burden), and potentially the inclusion of patient partners in governance, priority-setting, and dissemination.

Eligibility is broad and includes many types of U.S.-based organizations. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; tribal organizations other than federally recognized tribal governments; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The opportunity explicitly calls out additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. These inclusions reinforce the intent to build a truly national effort and to encourage participation from institutions that serve diverse populations and communities.

At the same time, the FOA places clear limits on foreign participation. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined in the NIH Grants Policy Statement, which generally means a U.S. applicant may include certain foreign elements when they are justified, well integrated, and necessary for the science (for example, a specific expertise, assay capability, or population access not available domestically), subject to NIH rules and approval.

Administratively, the opportunity is categorized as discretionary funding and uses the cooperative agreement mechanism. It is associated with multiple CFDA numbers (93.121, 93.213, 93.286, 93.313, 93.846, 93.853), reflecting NIH program areas that may support the initiative. The posting lists an original closing date of 2025-01-10 and a creation date of 2024-10-18. The award ceiling and expected number of awards are not specified in the provided summary, which typically means applicants should consult the full announcement for budget structure, allowable costs, anticipated award size, number of awards, project period, and any required consortium components (such as a coordinating center, data management, governance plans, or specific required cores).

Overall, TMD IMPACT is meant to create a coordinated national platform for TMD research that is interdisciplinary, collaborative, and grounded in patient needs, with the explicit goal of producing stronger evidence and accelerating the uptake of effective treatments into clinical care. Applicants considering this FOA should be prepared to propose a consortium-ready program with clear plans for collaboration, shared standards, training and capacity-building, and a translation pathway that connects research outputs to practical improvements in how TMDs are diagnosed, managed, and treated.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.286, 93.313, 93.846, 93.853.
• This funding opportunity was created on 2024-10-18.
• Applicants must submit their applications by 2025-01-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DE 25 003

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: